CD8A and neoplasm: As common recipes of vaccines against viruses, adjuvants of Toll‐like receptor 3/7/8/9 (TLR3/7/8/9) agonists improve anti‐tumor immunity by effectuating type I interferon (IFN) response and CD8+T cell activation.[92] Cytidine‐phospho‐guanosine oligonucleotides (CpG ODN), which are short single‐stranded synthetic DNA adjuvants, are broadly applied to camouflage pathogen‐associated molecular patterns (PAMPs), mobilizing immune cells through the triggering of the TLR9 signaling pathway in plasmacytoid DCs (pDCs) and B cells.[145] Kroll et al.